Nuclear translocation as a novel target for anti-HIV drugs

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 1, 2005, Pages 41-50

  Haffar, Omar ^a   Bukrinsky, Michael ^b  

^a International Therapeutics Inc   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

HIV 1; Integrase; Macrophage; Matrix protein; Nuclear import; T lymphocyte; Viral protein R

Indexed keywords

2 AMINO 4 (3,5 DIACETYLPHENYL)AMINO 1,6 DIMETHYLPYRIMIDINE; 3 (2 METHOXYPHENYL) 4 (3 TRIFLUOROMETHYL)PHENYL 1,2,4 OXADIAZOL 5 (4H) ONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; EFAVIRENZ; GLYCOPROTEIN; HYBRID PROTEIN; INTEGRASE; ITI 002; ITI 011; ITI 062; ITI 367; KARYOPHERIN ALPHA; KARYOPHERIN BETA; MATRIX PROTEIN; NELFINAVIR; NUCLEOPORIN; NUCLEOPORIN 98; OXADIAZOLE DERIVATIVE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; STYRYLQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VPR PROTEIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG STRUCTURE; DRUG TARGETING; GENE TRANSLOCATION; HEMATOPOIESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LONG TERM CARE; MACROPHAGE; NAUSEA; NONHUMAN; NUCLEAR IMPORT; REVERSE TRANSCRIPTION; REVIEW; T LYMPHOCYTE; VIRUS DNA CELL DNA INTERACTION; VIRUS MUTATION; VIRUS REPLICATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL NUCLEUS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 14044265670     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.1.41     Document Type: Review

References (76)

1. Witvrouw M, Van Maele B, Vercammen J et al. Novel inhibitors of HIV-1 integration, Curr. Drug Metab. 5, 291-304 (2004).
2. Stolk LM, Luers JF. Increasing number of anti-HIV drugs but no definate cure. Review of anti-HIV drugs. Pharm. World Sci. 26, 133-136(2004).
3. Lori F, Foli A, Lisziewicz J. Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. J. Antimicrob. Chemother. 50, 155-160 (2002).
4. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov. 2, 624-634 (2003).
5. Frenkel LM, Tobin NH. Understanding HIV-1 drug resistance. Ther. Drug Monit. 26, 116-121 (2004).
6. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16, 595-609 (2002).
7. Pantaleo G, Graziosi C, Demarest JF et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358 (1993).
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
9. Buckheit RW Jr. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert. Opin. Investig. Drugs 13(9), 933-958 (2004).
10. Varmus H. Lessons from the life cycle of retroviruses. Harvey Lect. 83, 35-56 (1987).
11. Nisole S, Saib A. Early steps of retrovirus replicative cycle. Retrovirology 1, 9 (2004).
12. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus Type 1 preintegration complexes: studies of organization and composition. J. Virol. 71, 5382-5390 (1997).
13. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus Type 1 (HIV-1) infection of nonproliferating human monocytes. J. Exp. Med. 174, 1477-1482 (1991).
14. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68, 510-516 (1994).
15. Emerman M, Bukrinsky M, Stevenson M. HIV-1 infection of nondividing cells. Nature 369, 107-108 (1994).
16. Bukrinsky MI, Sharova N, Dempsey MP et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl Acad. Sci. USA 89, 6580-6584 (1992).
17. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12, 2099-21080993).
18. Hatziioannou T, Goff SP. Infection of nondividing cells by rous sarcoma virus. J. Virol. 75, 9526-9531 (2001).
19. Katz RA, Greger JG, Darby K, Boimel P, Rall GF, Skalka AM. Transduction of interphase cells by avian sarcoma virus. J. Virol. 76, 5422-5434 (2002).
20. Heinzinger NK, Bukrinsky MI, Haggerty SA et al. The Vpr protein of human immunodeficiency virus Type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl Acad. Sci. USA 91, 7311-7315 (1994).
21. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus Type 1 allows the establishment of infection in macrophages and quiescent T-lymphocytes. Proc. Natl Acad. Sci. USA 91, 6992-6996 (1994).
22. Bouyac-Bertoia M, Dvorin JD, Fouchier RA et al. HIV-1 infection requires a functional integrase NLS. Mol. Cell. 7, 1025-1035 (2001).
23. Katz RA, Greger JG, Boimel P, Skalka AM. Human immunodeficiency virus Type 1 DNA nuclear import and integration are mitosis independent in cycling cells. J. Virol. 77, 13412-13417 (2003).
24. Wei X, Ghosh SK, Taylor ME et al. viral dynamics in human immunodeficiency virus Type 1 infection. Nature 373, 117-122 (1995).
25. Truant R, Cullen BR. the arginitie-rich domains present in human immunodeficiency virus Type 1 Tat and Rev function as direct importin β-dependent nuclear localization signals. Mol. Cell. Biol. 19, 1210-1217 (1999).
26. de Noronha CM, Sherman MP, Lin HW et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294, 1105-1108 (2001).
27. Gupta K, Ott D, Hope TJ, Siliciano RF, Boeke JD. A human nuclear shuttling protein that interacts with human immunodeficiency virus Type 1 matrix is packaged into virions. J. Virol. 74, 11811-11824 (2000).
28. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185 (2000).
29. Sirven A, Pflumio F, Zennou V et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96, 4103-4110 (2000).
30. Van Maele B, De Rijck J, De Clercq E, Debyser Z. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus Type 1 vector transduction. J. Virol. 77, 4685-4694 (2003).
31. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus Type 1 nuclear import. J. Virol. 76, 12087-12096(2002).
32. Limon A, Nakajima N, Lu R. Ghory HZ, Engelman A. Wild-type levels of nuclear localization and human immunodeficiency virus Type 1 replication in the absence of the central DNA flap. J. Virol. 76, 12078-12086(2002).
33. Bukrinsky MI, Haggerty S, Dempsey MP et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of nondividing cells. Nature 365, 666-669(1993).
34. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus Type 1 with viral nucleic acids following acute infection. Proc. Natl Acad. Sci. USA 90, 6125-6129 (1993).
35. Nadler SG, Tritschler D, Haffar OK, Blake J, Bruce AG, Cleaveland JS. Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequences. J. Biol. Chem. 272, 4310-4315 (1997).
36. Haffar OK, Popov S, Dubrovsky L et al. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J. Mol Biol. 299, 359-368 (2000).
37. Mattaj IW, Englmeier L. Nucleocytoplasmic transport: the soluble phase. Ann. Rev. Biochem. 67, 265-306, 265-306 (1998).
38. Rexach M, Blobel G. Protein import into nuclei: association and dissociation reactions involving transport substrate, transport factors, and nucleoporins. Cell 83, 683-692 (1995).
39. Gallay P, Stitt V, Mundy C, Oettinger M, Trono D. Role of the karyopherin pathway in human immunodeficiency virus Type 1 nuclear import. J. Virol. 70, 1027-1032 (1996).
40. Nemergut ME, Macara IG. Nuclear import of the ran exchange factor, RCC1, is mediated by at least two distinct mechanisms. J. Cell. Biol. 149, 835-850 (2000).
41. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. HIV-1 infection of nondividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 16, 4531-4539 (1997).
42. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus Type 1 matrix in macrophage infection. J. Virol. 69, 3949-3954 (1995).
43. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 17, 2699-2708 (1998).
44. Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl Acad. Sci. USA 94, 9825-9830 (1997).
45. Tsurutani N, Kubo M, Maeda Y et al. Identification of critical amino acid residues in human immunodeficiency virus Type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J. Virol. 74, 4795-4806 (2000).
46. Armon-Omer A, Graessmann A, Loyter A. A synthetic peptide bearing the HIV-1 integrase 161-173 amino acid residues mediates active nuclear import and binding to importin α: characterization of a functional nuclear localization signal. J. Mol. Biol. 336, 1117-1128 (2004).
47. Limon A, Devroe E, Lu R, Ghory HZ, Silver PA, Engelman A. Nuclear localization of human immunodeficiency virus Type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J. Virol. 76, 10598-10607 (2002).
48. Fassati A, Gorlich D, Harrison I, Zaytseva L, Mingot JM. Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. EMBO J. 22, 3675-3685 (2003).
49. Cherepanov P, Maertens G, Proost P et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278, 372-381 (2003).
50. Llano M, Vanegas M, Fregoso O et al. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegmdon complexes. J. Virol. 78, 9524-9537 (2004).
51. Maertens G, Cherepanov P, Debyser Z, Engelborghs Y, Engelman A. Identification and characterization of functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75. J. Biol. Chem. 279, 33421-33429 (2004).
52. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935-944 (1995).
53. Nie Z, Bergeron D, Subbramanian RA et al. The putative α-helix 2 of human immunodeficiency virus Type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells. J. Virol. 72, 4104-4115 (1998).
54. Jenkins Y, McEntee M, Weis K, Greene WC. Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. J. Cell. Biol. 143, 875-885 (1998).
55. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J. Biol. Chem. 273, 13347-13352 (1998).
56. Popov S, Rexach M, Zybarth G et al. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J. 17, 909-917 (1998).
57. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev. 12, 175-185(1998).
58. Le Rouzic E, Mousnier A, Rustum C et al. Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J. Biol. Chem. 277,45091-45098 (2002).
59. Fouchier RA, Meyer BE, Simon JH et al. Interaction of the human immunodeficiency virus Type 1 Vpr protein with the nuclear pore complex. J. Virol.. 72, 6004-6013 (1998).
60. Mekouar K, Mouscadet JF, Desmaele D et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 41, 2846-2857 (1998).
61. Mousnier A, Leh H, Mouscadet JF, Dargemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 66,783-788 (2004).
62. Gulizia J, Dempsey MP, Sharova N et al. Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal. J. Virol. 68, 2021-2025 (1994).
63. Friedler A, Zakai N, Karni O et al. Backbone cyclic peptide, which mimics the nuclear localization signal of human immunodeficiency virus Type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells. Biochemistry 37, 5616-5622 (1998).
64. Park SB, Ho TH, Reedy BM, Connolly MD, Standaert RF. Simple mimetics of a nuclear localization signal (NLS). Org. Lett. 5, 2437-2440 (2003).
65. Dubrovsky L, Ulrich P, Nuovo GJ, Manogue KR, Cerami A. Bukrinsky M. Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention. Mol. Med. 1, 217-230 (1995).
66. Al Abed Y, Dubrovsky L, Ruzsicska B, Seepersaud M, Bukrinsky M. Inhibition of HIV-1 nuclear import via schiff base formation with arylene bis(methyl ketone) compounds. Bioorg. Med. Chem. Lett. 12, 3117-3119 (2002).
67. Popov S, Dubrovsky L, Lee MA et al. Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. Proc. Natl Acad. Sci. USA 93, 11859-11864 (1996).
68. Haffar OK, Smithgall MD, Popov S et al. CNI-H0294, a nuclear importation inhibitor of the human immunodeficiency virus Type 1 genome, abrogates virus replication in infected activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 42,1133-1138 (1998).
69. Ebina H, Aoki J, Hatta S, Yoshida T, Koyanagi Y. Role of Nup98 in nuclear entry of human immunodeficiency virus Type 1 cDNA. Microbes. Infect. 6, 715-724 (2004).
70. Fried H, Kutay U. Nucleocytoplasmic transport: taking an inventory. Cell Mol. Life Sci. 60,1659-1688 (2003).
71. Fletcher TM, Brichacek B, Sharova N et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J. 15,6155-6165 (1996).
72. Fineberg K, Fineberg T, Graessmann A et al. Inhibition of nuclear import medited by the Rev-arginine rich motif by RNA molecules. Biochemistry 42, 2625-2633 (2003).
73. Friedler A, Friedler D, Luedtke NW, Tor Y, Loyter A, Gilon C. Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif. J. Biol. Chem. 275, 23783-23789 (2000).
74. Zhang H, Dornadula G, Pomerantz RJ. Endogenous reverse transcription of human immunodificiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J. Virol.. 70, 2809-2824 (1996).
75. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import J. Virol. 76, 12087-12096 (2002).
76. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC. Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J. Virol. 75, 1522-1532 (2001).